EXPRESSION ANALYSIS AND ITS CLINICAL USE IN BREAST TUMORS

##article.numberofdownloads## 24

##article.numberofviews## 49

Keywords

рак молочной железы
полногеномный экспрессионный анализ
прогноз

How to Cite

, , , , , , , , , , & . (2013). EXPRESSION ANALYSIS AND ITS CLINICAL USE IN BREAST TUMORS. Voprosy Onkologii, 59(1), 25–29. https://doi.org/10.37469/0507-3758-2013-59-1-25-29

Abstract

Рак молочной железы—это гетерогенное заболевание как по прогнозу и течению, так и по морфологическим характеристикам. Используемая в настоящее время клинико-патоморфологическая классификация опухолей носит, в первую очередь, описательный характер. Появившиеся относительно недавно методы высокопродуктивного молекулярно-генетического анализа позволяют разрабатывать профили экспрессии, которые возможно в ближайшем будущем не только позволят более точно определять прогноз течения болезни, а также ее чувствительность к лекарственным препаратам, но и дадут начало новым представлениям о канцерогенезе и патогенетических механизмах опухолевой пролиферации.

https://doi.org/10.37469/0507-3758-2013-59-1-25-29

##article.numberofdownloads## 24

##article.numberofviews## 49

PDF (Русский)

References

Abd El-Rehim D.M., Pinder S.E., Paish C.E. et al. Expression of luminal and basal cytokeratins in human breast carcinoma // J Pathol. - 2004. — Vol. 203 (2). — P. 661-671.

Ahr A., Holtrich U., Solbach C. et al. Molecular classification of breast cancer patients by gene expression profiling // J Pathol. — 2001. — Vol. 195 (3). — P. 312-320.

Augenlicht L.H., Wahrman M.Z., Halsey H. et al. Expression of cloned sequences in biopsies of human colonic tissue and in colonic carcinoma cells induced to differentiate in vitro // Cancer Res. — 1987. - Vol. 47 (22). — P. 6017-6021.

Bertucci F., Borie N., Ginestier C. et al. Identification and validation of an ERBB2 gene expression signature in breast cancers // Oncogene — 2004. — Vol. 23 (14). — P. 2564-2575.

Correa Geyer F., Reis-Filho J.S. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? // Int J Surg Pathol. — 2009. — Vol. 17 (4). — P. 285-302.

Desmedt C., Ruiz-Garcia E., Andre F. Gene expression predictors in breast cancer: current status, limitations and perspectives // Eur J Cancer — 2008. — Vol. 44 (18). — P. 2714-2720.

Dressman M.A., Baras A., Malinowski R. et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer // Cancer Res. — 2003. — Vol. 63 (9). — P. 2194-2199.

Goldhirsch A., Wood W.C., Gelber R.D. et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer // J Clin Oncol. — 2003. — Vol. 21 (17). — P. 3357-3365.

Gruvberger-Saal S.K., Bendahl P.O., Saal L.Het al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma // Clin Cancer Res. — 2007. — Vol. 13 (7). — P. 1987-1994.

Gruvberger-Saal S.K., Cunliffe H.E., Carr K.M., Hedenfalk I.A. Microarrays in breast cancer research and clinical practice--the future lies ahead // Endocr Relat Cancer. — 2006. — Vol. 13 (4). — P. 1017-1031.

Gruvberger S., Ringner M., Chen Y. et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns // Cancer Res. — 2001. — Vol. 61 (16). — P. 5979-5984.

Hess K.R., Anderson K., Symmans W.F. et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer // J Clin Oncol. — 2006. — Vol. 24 (26). — P. 4236-4244.

Iwao K., Matoba R., Ueno N. et al. Molecular classification of primary breast tumors possessing distinct prognostic properties // Hum Mol Genet. — 2002. — Vol. 11 (2). — P. 199-206.

Lee J.K., Havaleshko D.M., Cho H. et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery // Proc Natl Acad Sci U S A. — 2007. — Vol. 104 (32). — P. 13086-13091.

Livasy C.A., Karaca G., Nanda R. et al.Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma // Mod Pathol. -2006. — Vol. 19 (2). — P. 264-271.

Miller L.D., Smeds J., George J. et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival // Proc Natl Acad Sci U S A. - 2005. — Vol. 102 (38). — P. 13550-13555.

Paik S., Shak S., Tang G. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer // N Engl J Med. — 2004. — Vol. 351 (27). — P. 2817-2826.

Perou C.M., Sorlie T., Eisen M.B. et al. Molecular portraits of human breast tumours // Nature. — 2000. — Vol. 406 (6797). — P. 747-752.

Schena M., Shalon D., Davis R.W., Brown P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray // Science. — 1995. — Vol. 270 (5235). — P. 467-470.

Sorlie T., Perou C.M., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications // Proc Natl Acad Sci U S A. — 2001. — Vol. 98 (19). — P. 10869-10874.

Sorlie T.,Tibshirani R.,Parker J. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. // Proc Natl Acad Sci USA. — 2003. — Vol. 100 (14). — P. 8418-8423.

van‘t Veer L.J., Dai H., van de Vijver M.J. et al. Gene expression profiling predicts clinical outcome of breast cancer // Nature. — 2002. — Vol. 415 (6871). — P. 530-536.

van de Vijver M.J., He Y.D., van’t Veer L.J. et al. A geneexpression signature as a predictor of survival in breast cancer // N Engl J Med. - 2002. — Vol. 347 (25). — P. 1999-2009.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...